IGF1R and hepatocellular carcinoma: In the present study, we demonstrated that figitumumab possesses a high affinity for IGF1R/IR heterodimeric receptors as well as IGF1 homodimer receptors and inhibits the IGF/IGF1R signaling axis in gastric cancer and hepatocellular carcinoma cells.